Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Neoplasms, Sarcopenia

Thyroid Neoplasms

Dysplastic Nevus Syndrome, Melanoma, Hereditary Sensory and Autonomic Neuropathies

Carcinoma, Renal Cell

Advanced Renal Cell Carcinoma (aRCC)

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

Melanoma, Skin Neoplasms

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Renal Cell

Efficacy, Team

Melanoma, Motor Activity

Carcinoma, Non-Small-Cell Lung, Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasms

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

Lung Diseases, Interstitial

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Carcinoma, Hepatocellular, Liver Diseases

Stomach Neoplasms

Carcinoma, Renal Cell

Brain Neoplasms

Diabetes Mellitus

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Triple Negative Breast Neoplasms

Melanoma, Neoplasms

Neoplasm Metastasis

Kidney Neoplasms, Lung Neoplasms, Melanoma

Squamous Cell Carcinoma of Head and Neck, Deglutition Disorders, Head and Neck Neoplasms, Oropharyngeal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Uncommon Pathological Types of Lung Cancer

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms, Melanoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Advanced Colorectal Carcinoma

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma, Urinary Bladder Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Lung Squamous Cell Carcinoma Stage IV

Clinical Trials

ALCG-01

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

SARCO-CTI

NeoLATC

Oncomabs

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

International Multicentric Study ARON-1

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab

DELINOR

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

The Immune Assessment of PD-1 Antibody Therapy in Tumor

APiTOXMM

Imaging FDG Flare in Melanoma

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]

CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4]

EROS

A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

Development and Analysis of a Stool Bank for Cancer Patients

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

Axitinib Therapy Management Study

TREATMENT

NSCLC

I-STOP

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

PORTRAIT

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

PASIP

ST-ICI

Microbiome Immunotherapy Toxicity and Response Evaluation

QUASAR

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

PROBES

Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients

Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

Esporta

Immunotherapy in Lung Cancer: Treatment After IO Cessation.

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Efficacy and Safety of Eribulin in the Treatment of Advanced Breast Cancer

Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients

NIRPA

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy